N-(2-氨基乙基)-4-氟苯甲酰胺 | 94320-00-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2-氨基乙基)-4-氟苯甲酰胺
• 英文名称: N-(2-aminoethyl)-4-fluorobenzamide
• 英文别名: N-(2-aminoethyl)-p-fluorobenzamide
• CAS: 94320-00-0
• 化学式: C₉H₁₁FN₂O
• mdl: MFCD04354921
• 分子量: 182.198
• InChiKey: OTSNCERWNGFUEG-UHFFFAOYSA-N

物化性质

• 沸点：
  347.5±27.0 °C(Predicted)
• 密度：
  1.181±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-(2-氨基乙基)-4-氟苯甲酰胺 在 四(三苯基膦)钯 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 caesium carbonate 、 三乙胺 作用下， 以 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 24.33h， 生成 4-(3-amino-1H-indazol-4-yl)-N-(2-(4-fluorobenzamido)ethyl)benzamide
  参考文献：
  名称：

  Discovery of novel Bcr-AblT315I inhibitors with flexible linker. Part 1: Confirmation optimization of phenyl-1H-indazol-3-amine as hinge binding moiety

  摘要：

  As a continuation to our research, a series of novel Bcr-Abl inhibitors incorporated with 6-phenyl-1H-indazol-3-amine as hinge binding moiety (HBM) were developed based on confirmation analysis. Biological results indicated that these compounds exhibited an enhanced inhibition against Bcr-Abl(wT) and Bcr-Abl(T3151) in kinases assays, along with improved anti-proliferative activities in K562 cell assays. In particular, compound Y9 displayed comparable potency with that of imatinib. It potently inhibited Bcr-Abl(wT) and Bcr-Abl(T3151) kinases with IC50 of 0.043 mu M and 0.17 mu M, respectively. Furthermore, compound Y9 inhibited the proliferation of K562 and K562R cells with IC50 of 1.65 mu M and 5.42 mu M, respectively. Therefore, 6-phenyl-1H-indazol-3amine as HBM, combined with flexible linker, is a successful strategy contribute to research on T315I mutant resistance, and compound Y9 could be served as a starting point for further optimization. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.05.091
• 作为产物：
  描述：

  对氟苯甲酸甲酯 以 乙二胺 为溶剂， 生成 N-(2-氨基乙基)-4-氟苯甲酰胺
  参考文献：
  名称：

  Benzamide derivatives

  摘要：

  苯甲酰胺的化学式为##STR1##其中R.sup.1和R.sup.2分别独立地为氢、卤素、低碳烷基、低碳氧基、氰基、三氟甲基、磺酰胺基、单(低碳烷基)磺酰胺基或二(低碳烷基)磺酰胺基，或者R.sup.1和R.sup.2在相邻碳原子上共同形成亚甲二氧基基团，但R.sup.1为溴在3位时，R.sup.2与氢不同，它们的药用可接受的酸盐具有低毒性的单胺氧化酶抑制作用，因此可用于治疗抑郁症和帕金森病。

  公开号：

  US05238962A1

文献信息

• Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting V600EBRAF
  作者：Mohammed S. Abdel-Maksoud、Eslam M.H. Ali、Usama M. Ammar、Karim I. Mersal、Kyung Ho Yoo、Chang-Hyun Oh

  DOI：10.1016/j.bmc.2020.115493

  日期：2020.6

  Several pyrrolo[2,3-b]pyridine-based B-RAF inhibitors are well known and some of them are currently FDA approved as anticancer agents. Based on the structure of these FDA approved V600EB-RAF inhibitors, two series of pyrrolo[2,3-b]pyridine scaffold were designed and synthesized in attempt to develop new potent V600EB-RAF inhibitors. The 38 synthesized compounds were biologically evaluated for their

  几种基于吡咯并[2,3-b]吡啶的B-RAF抑制剂是众所周知的，其中一些目前已被FDA批准用作抗癌剂。根据这些FDA批准的V600EB-RAF抑制剂的结构，设计并合成了两个系列的吡咯并[2,3-b]吡啶骨架，以开发新的有效V600EB-RAF抑制剂。对38种合成化合物的单次剂量（10μM）的V600EB-RAF抑制作用进行了生物学评估。测试了具有高抑制百分数的化合物，以测定其相对于V600EB-RAF的IC50。化合物34e和35表现出最高的抑制作用，IC50值分别为0.085 µM和0.080 µM。为了进行过度的生物学评估，对合成的衍生物进行了六十种不同的人类癌细胞系测试。
• Procainamide assay, tracers, immunogens and antibodies
  申请人：ABBOTT LABORATORIES

  公开号：EP0199042A1

  公开（公告）日：1986-10-29

  The present invention is directed to a fluorescence polarization immunoassay for procainamide, to the various components needed for preparing and carrying out such an assay, and to methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for making them. The tracers and the immunogens are made from analogs of procainamide. A fluorescein moiety is included in the tracer while a poly(amino acid) forms a part of the immunogen. The assay is conducted by measuring the degree of ' polarization retention of plane polarized light that has been passed through a sample containing antiserum and tracer.

  该发明涉及一种用于普鲁卡因胺的荧光偏振免疫分析，以及制备和执行此类分析所需的各种组分，以及制造这些组分的方法。具体地，揭示了示踪剂、免疫原和抗体，以及制造它们的方法。示踪剂和免疫原是由普鲁卡因胺的类似物制成的。示踪剂中包含荧光基团，而多肽（氨基酸）是免疫原的一部分。该分析通过测量通过含有抗血清和示踪剂的样品的偏振保留度来进行，该样品已经通过平面偏振光。
• Discovery of Novel <i>N</i>-(Anthracen-9-ylmethyl) Benzamide Derivatives as ZNF207 Inhibitors Promising in Treating Glioma
  作者：Menghan Zhang、Yushi Ding、Mengkang Gao、Xiaolin Lu、Jun Tan、Fei Yu、Congying Gu、Lujun Gu、Xiameng Ren、Chenyan Hao、Liqin Ming、Kang Xu、Wenhao Mao、Yuqing Jin、Min Zhang、Linjun You、Zhanbo Wang、Yuanyuan Sun、Jingwei Jiang、Yong Yang、Dayong Zhang、Xinying Tang

  DOI：10.1021/acs.jmedchem.3c02241

  日期：2024.3.14

  Targeting tumor stemness is an innovative approach to cancer treatment. Zinc Finger Protein 207 (ZNF207) is a promising target for weakening the stemness of glioma cells. Here, a series of novel N-(anthracen-9-ylmethyl) benzamide derivatives against ZNF207 were rationally designed and synthesized. The inhibitory activity was evaluated, and their structure–activity relationships were summarized. Among

  针对肿瘤干性是一种创新的癌症治疗方法。锌指蛋白 207 (ZNF207) 是削弱神经胶质瘤细胞干性的一个有前景的靶点。在此，合理设计并合成了一系列针对ZNF207的新型N- (蒽-9-基甲基)苯甲酰胺衍生物。评估了抑制活性，并总结了它们的构效关系。其中， C16表现出最有效的抑制活性，其抑制球体形成的 IC 50值范围为 0.5-2.5 μM，抑制细胞毒性的 IC 50 值范围为 0.5-15 μM。此外，我们发现C16在体外可以阻碍肿瘤的发生和迁移并促进细胞凋亡。这些影响归因于干相关基因的下调。体内评估表明， C16表现出有效的血脑屏障渗透性，并且在皮下和原位神经胶质瘤模型中具有强大的功效。因此， C16可能作为靶向 ZNF207 的潜在先导化合物，对神经胶质瘤具有良好的治疗潜力。
• Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib
  作者：Xiaoyan Pan、Jinyun Dong、Ruili Shao、Ping Su、Yaling Shi、Jinfeng Wang、Langchong He

  DOI：10.1016/j.bmcl.2015.08.013

  日期：2015.10

  In order to expand the structural diversity of Bcr-Abl inhibitors, twenty hybrids (series E and P) have been synthesized and characterized based on Imatinib and GNF-2. Their biological activities were evaluated in vitro against human leukemia cells. Most compounds exhibited potent antiproliferative activity against K562 cells, especially for compounds E4, E5 and E7. Furthermore, these new hybrids were also screened for Abl kinase inhibitory activity, and some of them inhibited Abl kinase with low micromolar IC50 values. In particular, compound P3 displayed the most potent activity with IC50 value of 0.017 mu M comparable with that of Imatinib. Molecular docking studies indicated that these novel hybrids fitted well with the active site of Bcr-Abl. These results suggested the great potential of these compounds as novel Bcr-Abl inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.
• DA, PRADA, M.;JOOS, R.;KYBURZ, E.;WYSS, P. C.
  作者：DA, PRADA, M.、JOOS, R.、KYBURZ, E.、WYSS, P. C.

  DOI：——

  日期：——